Mark Nylen is a partner in the Corporate Practice. He regularly counsels both private and public companies on a variety of transactions, including mergers, acquisitions, venture capital financings and joint ventures. Mr. Nylen has significant experience advising both emerging and established companies in the life sciences, technology and financial services industries, among a range of other sectors.

Prior to joining WilmerHale, Mr. Nylen was a corporate associate at another large law firm in New York, where he advised on corporate governance matters and worked on both asset and equity acquisitions as well as mergers across a variety of industries.


    • Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), in its acquisition of ReNAgade Therapeutics
    • 3Play Media, Inc., a technology company that provides premium closed captioning, transcription, audio description and subtitling solutions in its acquisition by Riverside Partners
    • Affirmed Networks, a leader in wireless telecommunication equipments and solutions, in its sale to Microsoft Corporation
    • Aileron Therapeutics, a clinical stage chemoprotection oncology company, in its acquisition of Lung Therapeutics, a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments
    • Akamai, the world’s most distributed cloud, security and content platform, in its acquisitions of Asavie Technologies, Exceeda, Guardicore, Janrain and Soha Systems
    • Alkermes, a global biopharmaceutical company developing innovative medicines in the field of neuroscience, in its acquisition of Rodin Therapeutics
    • Cloud9 Technologies LLC, a leader in integrated cloud-based communication solutions, in its acquisition by Symphony Communication Services Holdings
    • Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, in its sale to Eli Lilly
    • DriveWealth, a pioneer in fractional investing and embedded finance, in its acquisition of Crypto-Systems, LLC, a company that offers tailored market-making services to platforms for digital assets to provide deep and stable liquidity
    • Endurance International Group, an IT services company specializing in web hosting, in its acquisition by Clearlake Capital Group for $3 billion
    • GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells therapies for immunology, in its $157 million Series A financing
    • Gemini Therapeutics, a precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration, in its merger with Disc Medicine, Inc., a privately held, clinical-stage biopharmaceutical company
    • IMARA, a clinical-stage biopharmaceutical company, in its sale of assets to Cardurion Pharmaceuticals and its subsequent merger with Enliven Therapeutics
    • Lexicon Pharmaceuticals, a biopharmaceutical company developing treatments for human disease, in the sale of Xermelo to TerSera
    • MKS Instruments, a global provider of technologies that enable advanced processes and improve productivity, in its acquisition of Newport Corporation
    • Nasdaq Private Market, a leading provider of liquidity solutions to private companies, in its $62.4 million Series B Financing
    • Novo Nordisk, a leading global healthcare company, in its strategic collaboration with Flagship Pioneering to create a portfolio of transformational medicines
    • PerkinElmer, a global leader committed to innovating for a healthier world, in its $591 million acquisition of Oxford Immunotec, a global leader of proprietary test kits for latent tuberculosis
    • TMX Group, in its strategic investment in VettaFi, a US-based, privately owned data, analytics, indexing, digital distribution, and thought leadership company
    • Viamet Pharmaceuticals, a pharmaceutical company that develops small molecule inhibitors via an enzyme binding approach for the treatment of various diseases, in its sale to NovaQuest Capital Management
    • WEX, the global commerce platform that simplifies the business of running a business, in its acquisition of Electronic Funds Source
    • Zaius, a customer data platform bringing the context of the customer to the experience creation and optimization process of digital experiences, in its acquisition by Optimizely (formerly Episerver), a leading provider of digital experience platform solutions

Insights & News


  • Education

    • JD, University of Pennsylvania Law School, 2012

      Associate Editor, Journal of Business Law
    • BA, Communications, Boston College, 2008

      magna cum laude
  • Admissions

    • Massachusetts

    • New York



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.